Tennessee-based Vilex, LLC announced its acquisition of DT MedTech, LLC. The acquisition includes DT MedTech’s Hintermann Series System™ Total Ankle Replacement (TAR).
Vilex Acquires DT MedTech and Total Ankle Replacement System
1 min read Premium comments
Secondary#dtmedtech#totalanklereplacement#vilex
Vilex is part of the Squadron Capital family of businesses. DT MedTech will become a wholly owned subsidiary of Vilex. DT MedTech will retain manufacturing control and continue to market its products internationally through its existing distribution network. The Vilex sales organization will promote the sale of the Hintermann Series System within the United States.
Developed by Professor Beat Hintermann, the TAR system includes the Hintermann Series H3® (H3) 3-piece, mobile-bearing TAR prosthesis and the Hintermann Series H2® (H2) 2-piece, semi-constrained TAR prosthesis. The H3 has been used for over 20 years. Both the H2 and H3 FDA clearance and are available in more than 30 countries.
Vilex CEO Dustin Leavitt commented on the acquisition: “The merging of our widely recognized Vilex product line in the U.S. with the globally-renowned, clinically-proven, Hintermann Series product portfolio, positions Vilex as a global leader in providing lower extremity surgical solutions.”
Leavitt continued, “The combined commercial channel now includes more than 50 distributors in the U.S. and over 25 distribution partners outside the U.S., comprising over 300 field representatives, and many long-standing institutional customers.”
OTW spoke with Shawn T. Huxel about the acquisition. Previously the DT MedTech executive vice president, Huxel was recently appointed to chief operating officer of Vilex. Huxel informed OTW that with this acquisition, Professor Hintermann has been able to realize his lifelong goal of entering the U.S. foot and ankle marketplace.
Leavitt added, “Vilex will work closely with Professor Hintermann as we continue worldwide distribution and introduce the Hintermann Series System into our U.S. sales channel.”
Huxel told OTW, “Dusty [Leavitt] and I are excited to position Vilex in the forefront of the global foot and ankle marketplace. The synergy between the Hintermann Series System®, Vilex’s existing product platform, DT MedTech, Vilex’s sales channel and new product developments will drive our leadership globally.”
Huxel continued, “In today’s world focused on evidence-based medicine, product quality and financial efficiencies, Vilex is uniquely positioned for success.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.